Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: A randomised phase 2/3 non-inferiority study (FIRIS study)

The Lancet Oncology

Volumn 11, Issue 9, 2010, Pages 853-860

  Muro, Kei ^a   Boku, Narikazu ^b   Shimada, Yasuhiro ^c   Tsuji, Akihito ^d   Sameshima, Shinichi ^e   Baba, Hideo ^f   Satoh, Taroh ^g   Denda, Tadamichi ^h   Ina, Kenji ⁱ   Nishina, Tomohiro ^j   Yamaguchi, Kensei ^k   Takiuchi, Hiroya ^l   Esaki, Taito ^m   Tokunaga, Shinya ⁿ   Kuwano, Hiroyuki ^o   Komatsu, Yoshito ^p   Watanabe, Masahiko ^q   Hyodo, Ichinosuke ^r   Morita, Satoshi ^s   Sugihara, Kenichi ^t  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d Kochi Health Sciences Center   (Japan)

^e GUNMA PREFECTURAL CANCER CENTER   (Japan)

^f KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h CHIBA CANCER CENTER   (Japan)

ⁱ Nagoya Memorial Hospital   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^k SAITAMA MEDICAL UNIVERSITY   (Japan)

^l OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^m National Hospital Organization   (Japan)

ⁿ OSAKA CITY GENERAL HOSPITAL   (Japan)

^o GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^q KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^r UNIVERSITY OF TSUKUBA   (Japan)

^s YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^t TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG COMBINATION; OTERACIL; PLATINUM COMPLEX; PRODRUG; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PRODRUGS; TEGAFUR; KAPLAN-MEIER ESTIMATE;

EID: 77956150646     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70181-9     Document Type: Article

References (26)

1. O'Neil BH, Goldberg RM Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008, 13:1074-1083.
2. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
3. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
4. Rougier P, Lepille D, Bennouna J, et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002, 13:1558-1567.
5. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
6. NCCN clinical practice guidelines in oncology National Comprehensive Cancer Network, (accessed May 17, 2010). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
7. Shirasaka T Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009, 39:2-15.
8. Goto A, Yamada Y, Yasui H, et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006, 17:968-973.
9. Yuki S, Komatsu Y, Sogabe S, et al. Phase II study of combination with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer (HGCSG0302): final analysis. 2009 ASCO Gastrointestinal Cancers Symposium; San Francisco, CA, USA; Jan 15-17, 2009. Abstract 463.
10. Tsunoda A, Yasuda N, Nakao K, et al. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 2009, 77:192-196.
11. Fuse N, Doi T, Ohtsu A, et al. Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 2008, 13:144-149.
12. Komatsu Y, Yuki S, Fuse N, et al. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Adv Ther 2010, published online July 6. 10.1007/s12325-010-0037-2.
13. Shiozawa M, Akaike M, Sugano N, et al. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2010, published online July 10. 10.1007/s00280-010-1278-0.
14. Brookmeyer R, Crowley J A confidence interval for the median survival time. Biometrics 1982, 38:29-41.
15. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008, 19:1720-1726.
16. Arkenau HT, Arnold D, Cassidy J, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008, 26:5910-5917.
17. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786.
18. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012.
19. Köhne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008, 19:920-926.
20. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008, 26:2118-2123.
21. Shirao K, Hoff PM, Ohtsu A, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004, 22:3466-3474.
22. Yen-Revollo JL, Goldberg RM, McLeod HL Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?. Clin Cancer Res 2008, 14:8-13.
23. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
24. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003, 21:807-814.
25. Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009, 27:2848-2854.
26. Haller DG, Rothenberg ML, Wong AO, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008, 26:4544-4550.